Torii Pharmaceutical Co., Ltd.

Tokyo Stock Exchange 4551.T

Torii Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2023: USD 851.39 M

Torii Pharmaceutical Co., Ltd. Shareholders' Equity is USD 851.39 M for the year ending December 31, 2023, a -6.33% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Torii Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2022 was USD 908.96 M, a -10.57% change year over year.
Torii Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2021 was USD 1.02 B, a -8.74% change year over year.
Torii Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2020 was USD 1.11 B, a 7.01% change year over year.
Torii Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2019 was USD 1.04 B, a 31.00% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

Tokyo Stock Exchange: 4551.T

Torii Pharmaceutical Co., Ltd.

CEO	Mr. Goichi Matsuda
IPO Date	Jan. 1, 2001
Location	Japan
Headquarters	Torii Nihonbashi Bldg.
Employees	583
Sector	Consumers Staples
Industries Personal Care Biotechnology Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Pet Food Pharmaceuticals Tobacco

Description

Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents, such as Riona for the treatment of hyperphosphatemia; and REMITCH, an oral therapeutic agent used for the treatment of pruritus in dialysis and liver disease patients. The company also provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; allergen immunotherapy tablets comprising CEDARCURE and MITICURE; and CORECTIM, a topical janus kinase (JAK) inhibitor. It markets its products primarily through medical representatives for medical professionals. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc.

Key trends

Past 5 years